No Detail Found!

Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes

Author(s)
Li Wu Department of Infectious Diseases, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei, China.
Pei-pei Luo Department of Infectious Diseases, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei, China.
Yan-hong Tian Department of Infectious Diseases, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei, China.
Lai-yin Chen Department of Infectious Diseases, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei, China; Department of infection, Baoding People’s Hospital, Baoding 071000, Hebei, China.
Yan-li Zhang Department of Infectious Diseases, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei, China.
Abstract
Objective: To observe the clinical efficacy of thymosin alpha 1 (Ta1) combined with multi-modality chemotherapy in patients with pulmonary tuberculosis (PTB) complicated with diabetes and discuss the effects of such combination therapy on lymphocyte subsets and sputum levels of cytokines. Methods: A total of 120 patients with PTB complicated with diabetes admitted to the Affiliated Hospital of North China University of Science and Technology from January 2017 to January 2018 were included in this study and randomly divided into an experimental group (Ta1 group, n=60) and a control group (n=60). Clinical efficacy and adverse drug reactions were observed and compared between the two groups. Blood samples were collected for lymphocyte (NK cell and T cell subsets) levels by flow cytometry, and sputum samples were collected for cytokine (IL-2, IFN-?, IL-4 and TNF-a) levels by ELISA. Results:Two groups showed no statistically significant difference in sputum culture-negative conversion rate, chest lesion absorption rate, and cavity closure rate (P>0.05) after 6 months of treatment. However, after 12 months, the sputum culture-negative conversion rate, chest lesion absorption rate, and cavity closure rate in the Ta1 group increased compared with the control group, and the differences were statistically significant (P0.05). Conclusion: Ta1 combined with multi-modality chemotherapy has a visible curative effect on PTB patients with diabetes as it can regulate immune function and reduce the levels of inflammatory cytokines. As a safe combination therapy, it seems promising for further use in clinical practice.
Publication Details
Page(s) 179-184
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 38, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Adverse reaction, T cell, Thymosin alpha 1, Sputum supernatant cytokine, Pulmonary tuberculosis complicated with diabetes mellitus, Immunoregulation
0

Citations

0

Downloads

67

Views